Healthcare Providers Can Expect To Receive US$725 Reimbursement From CMS When Using NGS-based Sentosa(R) SQ HIV-1 Genotyping Assay

Published by
The Street

By PR Newswire FAIRFIELD, N.J., Jan. 7, 2022 /PRNewswire/ — Vela Diagnostics announced that its Sentosa ® SQ HIV-1 Genotyping Assay is covered for reimbursement from The Centers for Medicare and Medicaid (CMS) starting January 2022. Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare providers using the Sentosa ® SQ HIV-1 Genotyping Assay solution with the assigned descriptor for therapeutic diagnoses can expect a reimbursement of US$725 using CPT code 0219U for HIV gene analysis*. The Sentosa ® SQ HIV-1 Genotyping Assay is a sample-to-result solution that uses Ne…

Read More